PSMA-PET Imaging of High Risk Prostate Cancer-Cures

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

This study has now started accrual. It is a multi-institutional trial involving the use of PSMA PET/CT in high risk patients. The PSMA PET agent, F18 DCFPyl, is provided to sites by Progenics. The American College of Radiology will assist in archiving imaging and pathology. Approximately 4 patients have been accrued at the NCI site to date and accrual was interrupted by the COVID pandemic. To date we have seen excellent performance of the PSMA PET agent and the surgery has been successfully performed without incident.